Next Article in Journal
Emerging and Dynamic Biomedical Uses of Ferritin
Next Article in Special Issue
Radiolabelled Aptamers for Theranostic Treatment of Cancer
Previous Article in Journal
Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients
Previous Article in Special Issue
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Review

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities

1
Istituto per l’Endocrinologia e l’Oncologia Sperimentale G. Salvatore (IEOS), CNR, 80145 Naples, Italy
2
Istituto di Biostrutture e Bioimmagini, CNR, 80145 Naples, Italy
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2018, 11(4), 123; https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040123
Received: 16 October 2018 / Revised: 2 November 2018 / Accepted: 9 November 2018 / Published: 13 November 2018
(This article belongs to the Special Issue Aptamer-Based Diagnostics and Therapeutics)
Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds great promise to the search for novel targetable biomarkers, and aptamer-based molecular approaches have the potential to overcome obstacles of current imaging and therapy modalities. In this review, we highlight recent advances in oligonucleotide aptamers used as imaging and/or therapeutic agents in TNBC, discussing the potential options to discover, image and hit new actionable targets in TNBC. View Full-Text
Keywords: aptamer; chemoresistance; targeted imaging; targeted therapy; TNBC; tumor microenvironment; SELEX aptamer; chemoresistance; targeted imaging; targeted therapy; TNBC; tumor microenvironment; SELEX
Show Figures

Figure 1

MDPI and ACS Style

Camorani, S.; Fedele, M.; Zannetti, A.; Cerchia, L. TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities. Pharmaceuticals 2018, 11, 123. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040123

AMA Style

Camorani S, Fedele M, Zannetti A, Cerchia L. TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities. Pharmaceuticals. 2018; 11(4):123. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040123

Chicago/Turabian Style

Camorani, Simona, Monica Fedele, Antonella Zannetti, and Laura Cerchia. 2018. "TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities" Pharmaceuticals 11, no. 4: 123. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040123

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop